<DOC>
	<DOCNO>NCT00624351</DOCNO>
	<brief_summary>The primary objective study assess dose response dose frequency epratuzumab patient SLE .</brief_summary>
	<brief_title>Study Epratuzumab Serologically-positive Systemic Lupus Erythematosus ( SLE ) Patients With Active Disease</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Positive ANA result visit 1 Current diagnosis systemic lupus erythematosus ( SLE ) American College Rheumatology revise criterion least 4 11 criterion meet Active moderate severe SLE disease activity demonstrate British Isles Lupus Assessment Group ( BILAG ) A level disease activity least one body/organ system BILAG B level disease activity least two body/organ system BILAG A level disease present If antimalarial , dose regimen must stable 4 week prior study entry . Patients receive live vaccination within 2 week prior visit 1 course study Active severe SLE disease activity involve central nervous system ( CNS ) ( define BILAG neurologic A level activity ) include transverse myelitis , psychosis seizure Active severe SLE disease activity involve Renal system ( defined BILAG renal level A activity Grade III high World Health Organization ( WHO ) nephritis ) serum creatinine &gt; 2.5mg/dL clinically significant serum creatinine increase within prior 4 week proteinuria &gt; 3.5gm/day Patients history antiphospholipid antibody syndrome AND use oral anticoagulant antiplatelet treatment Patients history chronic infection , recent significant infection , current sign symptom may indicate infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>B-Cell immunotherapy</keyword>
</DOC>